pharma · Ulcerative Colitis · Multiple Myeloma
AbbVie Deutschland GmbH
AbbVie Deutschland GmbH & Co. KG
AbbVie Deutschland GmbH patent portfolio — 23 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Wiesbaden, DE
- Founded
- 2018
- Employees
- 101
- Programs
- 102
- Drugs
- 119
- Patents
- 23
AbbVie Deutschland GmbH patents
23 pharmaceutical patents indexed for AbbVie Deutschland GmbH. 0 expire within 24 months.
AbbVie Deutschland GmbH has 23 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
WO 2024243450
MÉTHODES DE TRAITEMENT UTILISANT DES CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-C-MET
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
CA 3259391
POLYTHÉRAPIE ANTI-GARP-TGF-β1/PD-1
granted -
CA 3245150
COMBINAISONS AVEC UN ANTICORPS ANTI-CD39 HUMAIN, UN ANTICORPS ANTI-PD-1 HUMAIN ET UNE CHIMIOTHÉRAPIE CONTRE LE CANCER GASTRIQUE
granted -
US 2023174645
ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSIS
granted -
CA 3235096
METHODES DE TRAITEMENT DE L'ANEMIE CAUSEE PAR UNE MALADIE RENALE
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 2022169620
SPIRO-CYCLIC AMINE DERIVATIVES AS S1P MODULATORS
granted -
CA 3177888
ANTICORPS ANTI-HEMOJUVELINE (HJV) DE TRAITEMENT DE L'ANEMIE DE MALADIES CHRONIQUES
granted -
US 2021128573
DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX
granted -
EP 3668502
MAKROCYCLISCHE MCL-1-INHIBITOREN UND VERFAHREN ZUR VERWENDUNG
granted -
US 2020155578
Pharmaceutical Formulations for Subcutaneous Administration
granted -
CA 3094934
FORMULATIONS AQUEUSES STABLES D'ANTICORPS ANTI-TAU
granted -
US 2019144465
Macrocyclic MCL-1 inhibitors and methods of use
granted -
WO 2019048531
NANOPARTICULES MODIFIÉES PAR L'ALBUMINE PORTANT UN LIGAND DE CIBLAGE
granted -
US 2019055264
Macrocyclic MCL-1 inhibitors and methods of use
granted -
WO 2019016112
COMPOSÉS DE QUINOLÉINE À SUBSTITUTION EN POSITIONS 1, 2, 3 ET 4 UTILISÉS EN TANT QUE MODULATEURS DE S1P
granted -
WO 2018175449
COMPOSÉS DE PROLINE AMIDE ET LEURS ANALOGUES D'AZÉTIDINE PORTANT UN RADICAL BENZYLE À SUBSTITUTION SPÉCIFIQUE
granted -
WO 2018083171
COMPOSÉS SPIRO EN TANT QUE MODULATEURS DE S1P
granted -
US 2017349653
METHODS FOR TREATING SPINAL CORD INJURY AND PAIN
granted -
US 2017260158
QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
granted -
US 2017174672
FUSED (HETERO)CYCLIC COMPOUNDS AS S1P MODULATORS
granted -
WO 2017089458
HEXAHYDROPYRAZINOBENZ- OU -PYRIDO-OXAZÉPINES TRANSPORTANT UN SUBSTITUANT CONTENANT DE L'OXYGÈNE ET SON UTILISATION POUR LE TRAITEMENT D'AFFECTIONS CONDITIONNÉES PAR 5-HT2C
granted
Frequently asked questions
How many patents does AbbVie Deutschland GmbH have?
23 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do AbbVie Deutschland GmbH patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.